Michael W. Sill, Ph.D. - Publications

Affiliations: 
2000 University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Statistics

62 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27217446 DOI: 10.1200/JCO.2015.65.8153  0.96
2015 Tewari KS, Sill MW, Monk BJ, Penson RT, Long HJ, Poveda A, Landrum LM, Leitao MM, Brown J, Reid TJ, Michael HE, Moore DH. Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 5480-7. PMID 26672085 DOI: 10.1158/1078-0432.CCR-15-1346  0.96
2015 McMeekin DS, Sill MW, Walker JL, Moore KN, Waggoner SE, Thaker PH, Rizack T, Hoffman JS, Fracasso PM. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 138: 36-40. PMID 25958319 DOI: 10.1016/j.ygyno.2015.04.038  0.96
2015 Coleman RL, Sill MW, Thaker PH, Bender DP, Street D, McGuire WP, Johnston CM, Rotmensch J. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 138: 30-5. PMID 25887099 DOI: 10.1016/j.ygyno.2015.04.005  0.96
2015 Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 137: 386-91. PMID 25818403 DOI: 10.1016/j.ygyno.2015.03.042  0.96
2015 Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study Gynecologic Oncology. DOI: 10.1016/j.ygyno.2015.07.018  0.96
2015 Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial Gynecologic Oncology. DOI: 10.1016/j.ygyno.2015.07.006  0.96
2014 Dizon DS, Sill MW, Schilder JM, McGonigle KF, Rahman Z, Miller DS, Mutch DG, Leslie KK. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology. 135: 441-5. PMID 25312396 DOI: 10.1016/j.ygyno.2014.10.001  0.96
2014 Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology. 135: 38-43. PMID 25019571 DOI: 10.1016/j.ygyno.2014.07.083  0.96
2014 Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. Gynecologic Oncology. 133: 433-8. PMID 24708919 DOI: 10.1016/j.ygyno.2014.03.571  0.96
2014 Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. The New England Journal of Medicine. 370: 734-43. PMID 24552320 DOI: 10.1056/NEJMoa1309748  0.96
2014 Martin LP, Sill M, Shahin MS, Powell M, DiSilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 132: 526-30. PMID 24361733 DOI: 10.1016/j.ygyno.2013.12.018  0.96
2013 Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 129: 486-94. PMID 23438670 DOI: 10.1016/j.ygyno.2013.02.019  0.96
2013 Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecologic Oncology. 129: 86-91. PMID 23321064 DOI: 10.1016/j.ygyno.2013.01.006  0.96
2012 Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecologic Oncology. 127: 456-61. PMID 22960004 DOI: 10.1016/j.ygyno.2012.08.030  0.96
2012 Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 127: 506-10. PMID 22943879 DOI: 10.1016/j.ygyno.2012.08.037  0.96
2012 Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 127: 538-43. PMID 22922531 DOI: 10.1016/j.ygyno.2012.08.020  0.96
2012 Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecologic Oncology. 127: 345-50. PMID 22885469 DOI: 10.1016/j.ygyno.2012.07.127  0.96
2012 Sill MW, Rubinstein L, Litwin S, Yothers G. A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials. Clinical Trials (London, England). 9: 385-95. PMID 22811448 DOI: 10.1177/1740774512450101  0.96
2012 McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, Rubin SC, Rose PG, Small L, Benbrook DM. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecologic Oncology. 127: 356-61. PMID 22796461 DOI: 10.1016/j.ygyno.2012.07.095  0.96
2012 Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, Buening BJ, Sorosky JI, Fruehauf JP, Burger RA. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecologic Oncology. 126: 375-80. PMID 22683587 DOI: 10.1016/j.ygyno.2012.06.002  0.96
2012 Aghajanian C, Sill MW, Secord AA, Powell MA, Steinhoff M. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. Gynecologic Oncology. 126: 424-7. PMID 22634397 DOI: 10.1016/j.ygyno.2012.05.024  0.96
2012 Rose PG, Sill MW, McMeekin DS, Ahmed A, Salani R, Yamada SD, Wolfson AH, Fusco N, Fracasso PM. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study. Gynecologic Oncology. 125: 158-62. PMID 22198338 DOI: 10.1016/j.ygyno.2011.12.431  0.96
2012 Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 125: 54-8. PMID 22155262 DOI: 10.1016/j.ygyno.2011.12.417  0.96
2012 Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecologic Oncology. 124: 563-8. PMID 22138229 DOI: 10.1016/j.ygyno.2011.11.035  0.96
2012 Garcia AA, Sill MW, Lankes HA, Godwin AK, Mannel RS, Armstrong DK, Carolla RL, Liepman MK, Spirtos NM, Fischer EG, Leslie KK. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecologic Oncology. 124: 569-74. PMID 22037316 DOI: 10.1016/j.ygyno.2011.10.022  0.96
2011 Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecologic Oncology. 123: 182-6. PMID 21820161 DOI: 10.1016/j.ygyno.2011.07.016  0.96
2011 Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecologic Oncology. 123: 19-26. PMID 21752435 DOI: 10.1016/j.ygyno.2011.06.022  0.96
2011 Santin AD, Sill MW, McMeekin DS, Leitao MM, Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecologic Oncology. 122: 495-500. PMID 21684583 DOI: 10.1016/j.ygyno.2011.05.040  0.96
2011 Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2259-65. PMID 21537039 DOI: 10.1200/JCO.2010.32.6397  0.96
2011 Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecologic Oncology. 121: 455-61. PMID 21414654 DOI: 10.1016/j.ygyno.2011.02.013  0.96
2011 Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecologic Oncology. 121: 303-8. PMID 21329967 DOI: 10.1016/j.ygyno.2011.01.030  0.96
2011 Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 121: 264-8. PMID 21277623 DOI: 10.1016/j.ygyno.2010.12.358  0.96
2011 Herzog TJ, Sill MW, Walker JL, O'Malley D, Shahin M, DeGeest K, Weiner SA, Mutch D, DeBernardo RL, Lentz SS. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecologic Oncology. 120: 454-8. PMID 21168198 DOI: 10.1016/j.ygyno.2010.11.008  0.96
2011 Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, De Geest K, Bonebrake AJ, Walker JL. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecologic Oncology. 120: 459-63. PMID 21144560 DOI: 10.1016/j.ygyno.2010.11.012  0.96
2011 Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 69-75. PMID 21098323 DOI: 10.1200/JCO.2009.26.7856  0.96
2011 Kunos CA, Sill MW, Buekers TE, Walker JL, Schilder JM, Yamada SD, Waggoner SE, Mohiuddin M, Fracasso PM. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecologic Oncology. 120: 224-8. PMID 21075438 DOI: 10.1016/j.ygyno.2010.10.018  0.96
2011 Sill MW, Monk BJ. Comments on: "Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens" (Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, de Geest K, et al. Gynecol Oncol. 2011 Mar;120(3):459-63) Gynecologic Oncology. 122: 462-463. DOI: 10.1016/j.ygyno.2011.05.026  0.96
2010 Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecologic Oncology. 119: 484-90. PMID 20870280 DOI: 10.1016/j.ygyno.2010.08.016  0.96
2010 Tiersten AD, Sill MW, Knight D, Muggia F, Garcia AA, Swensen R, Warshal DP, Mannel RS, Fracasso PM. A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 118: 303-7. PMID 20547415 DOI: 10.1016/j.ygyno.2010.05.020  0.96
2010 Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecologic Oncology. 117: 248-54. PMID 20189232 DOI: 10.1016/j.ygyno.2010.01.002  0.96
2010 Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 116: 15-20. PMID 19840887 DOI: 10.1016/j.ygyno.2009.09.025  0.96
2010 Sill MW, Fleming G. In Re: Re: "Phase II trial of trastuzumab in women with advanced or recurrent HER2-positive endometrial carcinoma: A Gynecologic Oncology Group Study" Gynecologic Oncology. 118: 96-97. DOI: 10.1016/j.ygyno.2010.03.005  0.96
2009 Sill MW, Sampson AR. Drop-the-Losers Design: Binomial Case. Computational Statistics & Data Analysis. 53: 586-595. PMID 20047003 DOI: 10.1016/j.csda.2008.07.031  0.96
2009 Hensley ML, Sill MW, Scribner DR, Brown J, Debernardo RL, Hartenbach EM, McCourt CK, Bosscher JR, Gehrig PA. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecologic Oncology. 115: 460-5. PMID 19811811 DOI: 10.1016/j.ygyno.2009.09.011  0.96
2009 Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4649-55. PMID 19720909 DOI: 10.1200/JCO.2009.21.8909  0.96
2009 Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 19: 929-33. PMID 19574787 DOI: 10.1111/IGC.0b013e3181a83467  0.96
2009 Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1069-74. PMID 19139430 DOI: 10.1200/JCO.2008.18.9043  0.96
2008 Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecologic Oncology. 111: 455-60. PMID 18829087 DOI: 10.1016/j.ygyno.2008.07.049  0.96
2008 Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3418-25. PMID 18612157 DOI: 10.1200/JCO.2007.14.3420  0.96
2008 Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecologic Oncology. 110: 329-35. PMID 18597837 DOI: 10.1016/j.ygyno.2008.05.008  0.96
2008 Heavey EJ, Moysich KB, Hyland A, Druschel CM, Sill MW. Female adolescents' perceptions of male partners' pregnancy desire. Journal of Midwifery & Women's Health. 53: 338-44. PMID 18586187 DOI: 10.1016/j.jmwh.2007.12.002  0.96
2008 Heavey EJ, Moysich KB, Hyland A, Druschel CM, Sill MW. Differences in pregnancy desire among pregnant female adolescents at a state-funded family planning clinic. Journal of Midwifery & Women's Health. 53: 130-7. PMID 18308262 DOI: 10.1016/j.jmwh.2007.09.005  0.96
2008 Heavey EJ, Moysich KB, Hyland A, Druschel CM, Sill MW. Differences in contraceptive choice among female adolescents at a state-funded family planning clinic. Journal of Midwifery & Women's Health. 53: 45-52. PMID 18164433 DOI: 10.1016/j.jmwh.2007.07.010  0.96
2008 Kavanagh JJ, Sill MW, Ramirez PT, Warshal D, Pearl ML, Morgan MA, Mackey D. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study International Journal of Gynecological Cancer. 18: 460-464. PMID 17854432 DOI: 10.1111/j.1525-1438.2007.01053.x  0.96
2007 Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 5165-71. PMID 18024863 DOI: 10.1200/JCO.2007.11.5345  0.96
2007 McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecologic Oncology. 106: 596-603. PMID 17597196 DOI: 10.1016/j.ygyno.2007.05.013  0.96
2007 McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecologic Oncology. 105: 508-16. PMID 17306350 DOI: 10.1016/j.ygyno.2007.01.019  0.96
2007 Sill MW, Sampson AR. Extension of a two-stage conditionally unbiased estimator of the selected population to the bivariate normal case Communications in Statistics - Theory and Methods. 36: 801-813. DOI: 10.1080/03610920601034072  0.96
2005 Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5539-48. PMID 16061871 DOI: 10.1158/1078-0432.CCR-05-0462  0.96
2005 Sampson AR, Sill MW. Drop-the-losers design: normal case. Biometrical Journal. Biometrische Zeitschrift. 47: 257-68; discussion 2. PMID 16053251 DOI: 10.1002/bimj.200410119  0.96
2004 Brady MF, Sill MW. Biostatistics and Clinical Trials Gynecologic Cancer: Controversies in Management. 865-881. DOI: 10.1016/B978-0-443-07142-3.50069-5  0.96
Show low-probability matches.